Sorrento Therapeutics, Inc. (SRNEQ)

OTCMKTS: SRNEQ · Delayed Price · USD
0.0300
+0.0010 (3.45%)
Apr 12, 2024, 3:52 PM EDT - Market closed
Market Cap 16.54M
Revenue (ttm) 64.27M
Net Income (ttm) -548.10M
Shares Out 551.28M
EPS (ttm) -1.12
PE Ratio n/a
Forward PE 1.10
Dividend n/a
Ex-Dividend Date n/a
Volume 13,730
Open 0.0200
Previous Close 0.0290
Day's Range 0.0200 - 0.0310
52-Week Range 0.0001 - 0.4190
Beta 2.29
Analysts n/a
Price Target n/a
Earnings Date n/a

About SRNEQ

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 949
Stock Exchange OTCMKTS
Ticker Symbol SRNEQ
Full Company Profile

Financial Performance

In 2022, SRNEQ's revenue was $62.84 million, an increase of 18.78% compared to the previous year's $52.90 million. Losses were -$572.84 million, 33.7% more than in 2021.

Financial Statements

News

Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that it has entered into a purchase agreement da...

17 days ago - Newsfile Corp

Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person

Vancouver, British Columbia--(Newsfile Corp. - May 8, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that Mr.

5 weeks ago - Newsfile Corp

DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing

Bremen, Indiana--(Newsfile Corp. - May 1, 2024) - Digger Specialties Inc. (DSI), a leading manufacturer of outdoor living products, is pleased to announce the introduction of Westbury® Sorrento Mesh R...

6 weeks ago - Newsfile Corp

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

Other symbols: VRPX
3 months ago - Business Wire

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to tre...

Other symbols: SCLX
9 months ago - PRNewsWire

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive topline results of a pivotal Phase 3 study of Sorrento's oral Mpro inhibitor...

9 months ago - GlobeNewsWire

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.

10 months ago - GlobeNewsWire

Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid

SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "the Debtor"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to t...

11 months ago - PRNewsWire

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer,...

11 months ago - GlobeNewsWire

Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders

SAN DIEGO , July 20, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, in...

Other symbols: SCLX
11 months ago - PRNewsWire

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ) today announced positive results from a China phase IIa study of Abivertinib on R/R MZL and its plan for a pivotal...

1 year ago - GlobeNewsWire

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced today the full enrollment in a pivotal Phase 3 study of Sorrento's oral Mpro inhibitor, Ovydso (STI-1558...

1 year ago - GlobeNewsWire

Sorrento Therapeutics, Inc.'s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock

SAN DIEGO , June 15, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, in...

1 year ago - PRNewsWire

Gold Hunter Resources Completes the Sale of Certain Properties to Sorrento Resources

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce, further to its press release on June 6, ...

1 year ago - Newsfile Corp

Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded a $4.6 million contract from the National Institute of Allergy and...

1 year ago - GlobeNewsWire

Gold Hunter Resources Inc. Sells a Portion of Its Newfoundland Projects to Sorrento Resources

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce it has entered into a mineral property pur...

1 year ago - Newsfile Corp

Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Ther...

1 year ago - GlobeNewsWire

Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts

SAN DIEGO , May 14, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, int...

1 year ago - PRNewsWire

Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend

SAN DIEGO , April 25, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, i...

1 year ago - PRNewsWire

Sorrento Therapeutics, Inc.'s Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock

SAN DIEGO , April 4, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, in...

Other symbols: SCLX
1 year ago - PRNewsWire

Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing

SAN DIEGO , March 29, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, i...

1 year ago - PRNewsWire

Court Confirms Sorrento Therapeutics, Inc.'s $125 Million Arbitration Award Against NantPharma, LLC

SAN DIEGO , March 17, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, a...

1 year ago - PRNewsWire

Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, ...

1 year ago - PRNewsWire

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued “Frequently Aske...

1 year ago - GlobeNewsWire

Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously issued “Frequently Asked Questions” document under the “Inv...

1 year ago - GlobeNewsWire